SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Fong James K

(Last) (First) (Middle)
C/O CTI BIOPHARMA CORP.
3101 WESTERN AVENUE, SUITE 800

(Street)
SEATTLE WA 98121

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/28/2022
3. Issuer Name and Ticker or Trading Symbol
CTI BIOPHARMA CORP [ CTIC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 3,565 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 04/12/2022 Common Stock 360 60.5 D
Stock Option (right to buy) (2) 03/24/2024 Common Stock 2,430 35.7 D
Stock Option (right to buy) (3) 03/17/2025 Common Stock 3,700 19.4 D
Stock Option (right to buy) (4) 05/18/2026 Common Stock 8,250 4.475 D
Stock Option (right to buy) (5) 03/01/2027 Common Stock 10,000 4.33 D
Stock Option (right to buy) (6) 09/29/2027 Common Stock 58,750 3.19 D
Stock Option (right to buy) (7) 05/16/2028 Common Stock 23,340 4.14 D
Stock Option (right to buy) (8) 02/19/2029 Common Stock 288,000 0.9489 D
Stock Option (right to buy) (9) 06/05/2030 Common Stock 210,000 1 D
Stock Option (right to buy) (10) 03/10/2031 Common Stock 115,000 3.3 D
Stock Option (right to buy) (11) 09/23/2031 Common Stock 210,000 3.05 D
Explanation of Responses:
1. This option represents the right to purchase 360 shares of the Issuer's common stock and is fully vested.
2. This option represents the right to purchase 2,430 shares of the Issuer's common stock and is fully vested.
3. This option represents the right to purchase 3,700 shares of the Issuer's common stock and is fully vested.
4. This option represents the right to purchase 8,250 shares of the Issuer's common stock and is fully vested.
5. This option represents the right to purchase 10,000 shares of the Issuer's common stock and is fully vested.
6. This option represents the right to purchase 58,750 shares of the Issuer's common stock and is fully vested.
7. This option represents the right to purchase 23,340 shares of the Issuer's common stock and is fully vested.
8. This option represents the right to purchase 288,000 shares of the Issuer's common stock and is fully vested.
9. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests in equal semi-annual installments beginning on September 11, 2020 through March 11, 2023, subject to the Reporting Person's continued service to the Issuer.
10. This option represents the right to purchase 115,000 shares of the Issuer's common stock and vests in approximately equal semi-annual installments beginning on September 10, 2021 through March 10, 2024, subject to the Reporting Person's continued service to the Issuer.
11. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests 25% annually beginning on February 28, 2023, subject to the Reporting Person's continued service to the Issuer.
Remarks:
Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney
/s/ Bruce J. Seeley, Attorney-in-fact for James K. Fong 03/11/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                                POWER OF ATTORNEY

        Know all by these presents that the undersigned hereby constitutes and
appoints each of Adam Craig, David Kirske and Bruce J. Seeley, and any of their
substitutes, signing singly, as the undersigned's true and lawful attorney-in-
fact to:

1.   prepare, execute in the undersigned's name and on the undersigned's
     behalf, and submit to the U.S. Securities and Exchange Commission (the
     "SEC") a Form ID, including amendments thereto, and any other document
     necessary or appropriate to obtain codes, passwords, and passphrases
     enabling the undersigned to make electronic filings with the SEC of
     reports require by the Securities Exchange Act of 1934 or any rule or
     regulation of the SEC;

2.   execute for and on behalf of the undersigned, in the undersigned's
     capacity as a director and/or officer of CTI BioPharma Corp. (the
     "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the
     Securities Exchange Act of 1934 and the rules thereunder;

3.   do and perform any and all acts for and on behalf of the undersigned which
     may be necessary or desirable to complete and execute any such Form 3, 4,
     or 5, complete and execute any amendment or amendments thereto, and timely
     file such form with the SEC and any securities exchange or similar
     authority; and

4.   take any other action of any type whatsoever in connection with the
     foregoing which, in the opinion of such attorney-in-fact, may be of
     benefit to, in the best interest of, or legally required by, the
     undersigned, it being understood that the documents executed by such
     attorney-in-fact on behalf of the undersigned pursuant to this Power of
     Attorney shall be in such form and shall contain such terms and conditions
     as such attorney-in-fact may approve in such attorney-in-fact's
     discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned also ratifies hereby any
action previously taken by each attorney-in-fact that would have been
authorized by this power of attorney if it has been in effect at the time such
action was taken. The undersigned acknowledges that each attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of March 3, 2022.

                                            By: /s/ James K. Fong
                                                -------------------------------
                                            Name: James K. Fong